FinanceAsianet Newsable
Indian pharma stocks tumble on Trump's generic drug tariff plan
in5points
Indian pharma stocks fell after Trump announced phased tariffs on generic drugs.
Expert analysis suggests minimal impact due to India's manufacturing cost advantage.
US subsidiaries of Indian firms and regulatory hurdles for shifting production mitigate effects.
The tariff plan targets reducing reliance on foreign drug manufacturing.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically